

Disclosures

Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Amgen	Research/Research Grants ‡ AMG145	Significant (>= \$5,000)	Invasive CV Angio and Interventions Prevention
Arrowhead	Research/Research Grants ‡ Elevated and very high triglyceide trial	None (\$0)	Prevention
AstraZeneca Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ DELIVER	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ ARTS-HF	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boehringer-Ingelheim	Speaker's Bureau	Significant (>= \$5,000)	General Cardiology
Eli Lilly and Company	Research/Research Grants ‡ SUMMIT	Significant (>= \$5,000)	Prevention
Esperion	Research/Research Grants ‡ CLEAR OUTCOME	Significant (>= \$5,000)	Prevention
Esperion	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Regeneron	Research/Research Grants	Significant (>= \$5,000)	Prevention
Spouse/Domestic Partner/Immediate Household Member			
US Medical Innovations	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2016	Sudden death	Defendant	Sudden death and MVA	Significant (>= \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/26/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/26/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/26/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/26/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.